|
Targeted and timed release of therapeutics via bone anchoring
Abstract
USC researchers have developed a targeted and timed release of therapeutics via bone anchoring to treat sensorineural hearing loss (SNHL). This approach expands on bisphosphonates’ ability to target and remain at bone sites by implementing a specifically designed cleavable...
|
|
Broad spectrum antiviral drugs
Abstract
USC researchers have developed a novel prodrug platform that addresses all three issues with ANP antivirals. The technology provides a solution for the identification and synthesis of cidofovir prodrugs and related ANP antivirals that are much more potent then the parent drugs in vitro. The prodrugs show 10x...
|
|
Antifungal drug
Abstract
USC researchers have recently developed a novel approach to treat pathogenic fungal infections by blocking DNA processing in the fungal cell. They have designed and synthesized a compound that blocks the function of a BET bromodomain protein in Candida albicans, Bdf1, which controls expression of some 50 fungal genes. Importantly,...
|
|
Therapeutic for hearing loss
Abstract
USC researchers have developed a novel bisphosphonate conjugate of DHF (Ris-DHF). Ris-DHF increases neurite outgrowth in vitro, maintains this ability after binding to hydroxyapatite, and regenerates synapses in kainic acid-damaged cochlear organ of Corti explants dissected in vitro with attached SGNs. The results...
|
|
Abstract
USC researchers have developed a novel prodrug platform that address all three issues with ANP antivirals. Using this technology, they have synthesized prodrugs of cidofovir and related ANP antivirals that are much more potent that the parent drugs in vitro, show 10x higher oral bioavailability, and have promise of better safety profiles....
|